Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2014; 20(22): 6701-6706
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6701
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6701
Hepatitis C virus core antigen testing: Role in diagnosis, disease monitoring and treatment
Hans L Tillmann, GI/Hepatology, Duke Clinical Research Institute and Duke University, Durham, NC 27708, United States
Author contributions: Tillmann HL solely contributed to this paper.
Correspondence to: Hans L Tillmann, MD, GI/Hepatology, Duke Clinical Research Institute and Duke University, Duke South, Orange Zone, room 0349, P.O. Box 3913, Durham, NC 27708, United States. hans.tillmann@duke.edu
Telephone: +1-919-6684620 Fax: +1-919-6848857
Received: September 29, 2013
Revised: January 16, 2014
Accepted: March 12, 2014
Published online: June 14, 2014
Processing time: 260 Days and 10.3 Hours
Revised: January 16, 2014
Accepted: March 12, 2014
Published online: June 14, 2014
Processing time: 260 Days and 10.3 Hours
Core Tip
Core tip: Hepatitis C virus (HCV) core antigen can be a cost effective alternative to confirm HCV infection, though patients with low HCV RNA (< 1000 IU/mL) have a chance of being false negative. It could have a role in therapy monitoring, but that is currently not well enough studied.